Latanoprost
- Generic Name
- Latanoprost
- Brand Names
- Iyuzeh, Rocklatan, Xalacom, Xalatan, Xelpros, Catiolanze
- Drug Type
- Small Molecule
- Chemical Formula
- C26H40O5
- CAS Number
- 130209-82-4
- Unique Ingredient Identifier
- 6Z5B6HVF6O
- Background
Latanoprost is a prodrug analog of prostaglandin F2 alpha that is used to treat elevated intraocular pressure (IOP). It was initially approved by the FDA in 1998. Latanoprost is the first topical prostaglandin F2 alpha analog used for glaucoma treatment. It has been found to be well-tolerated and its use does not normally result in systemic adverse effects l...
- Indication
Latanoprost is indicated for the reduction of elevated intraocular pressure in patients who have been diagnosed with open-angle glaucoma or ocular hypertension. It is available as monotherapy or in a combination product with netarsudil or timolol.
...
- Associated Conditions
- Increased Intra Ocular Pressure (IOP), Ocular Hypertension, Open Angle Glaucoma (OAG)
- Associated Therapies
- -
A 28 Day Study of ONO-9054 Ophthalmic Solution in Subjects With Ocular Hypertension (OHT) or Open-angle Glaucoma (OAG)
- Conditions
- Interventions
- First Posted Date
- 2014-03-11
- Last Posted Date
- 2016-02-25
- Lead Sponsor
- Ono Pharmaceutical Co. Ltd
- Target Recruit Count
- 123
- Registration Number
- NCT02083289
- Locations
- 🇺🇸
Pasadena Clinical Site, Pasadena, California, United States
🇺🇸New York Clinical Site, New York, New York, United States
🇺🇸Morrow Clinical Site, Morrow, Georgia, United States
Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension
- Conditions
- Interventions
- First Posted Date
- 2014-02-11
- Last Posted Date
- 2018-08-22
- Lead Sponsor
- Nephron Pharmaceuticals Corporation
- Target Recruit Count
- 335
- Registration Number
- NCT02059278
Latanoprost for the Treatment of Menière's Disease
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2016-03-23
- Lead Sponsor
- Synphora AB
- Target Recruit Count
- 100
- Registration Number
- NCT01973114
- Locations
- 🇸🇪
Sunderby Sjukhus, Luleå, Sweden
🇸🇪Falu Lasarett, Falun, Sweden
🇸🇪Centralsjukhuset i Karlstad, Karlstad, Sweden
A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma
- Conditions
- Interventions
- First Posted Date
- 2013-08-06
- Last Posted Date
- 2017-12-02
- Lead Sponsor
- Inotek Pharmaceuticals Corporation
- Target Recruit Count
- 101
- Registration Number
- NCT01917383
- Locations
- 🇺🇸
Chiltern, Bristol, Tennessee, United States
Study to Compare the Safety and Efficacy of ALZ-1101 to Latanoprost in Patients With Intraocular Pressure Inadequately Controlled by Latanoprost
- Conditions
- Interventions
- First Posted Date
- 2013-07-11
- Last Posted Date
- 2014-09-30
- Lead Sponsor
- Alleanza Pharmaceuticals, Inc.
- Target Recruit Count
- 63
- Registration Number
- NCT01896180
Latanoprost/Brinzolamide BID Versus Latanoprost BID in Patients With OAG or OH
- Conditions
- Interventions
- First Posted Date
- 2012-11-06
- Last Posted Date
- 2014-12-11
- Lead Sponsor
- Adapt Produtos Oftalmológicos Ltda.
- Registration Number
- NCT01721707
- Locations
- 🇧🇷
Department of Ophthalmology / Hospital São Paulo, São Paulo, Brazil
24-hour Control of Intraocular Pressure (IOP) in Ocular Hypertension
- Conditions
- Interventions
- First Posted Date
- 2012-08-02
- Last Posted Date
- 2012-08-02
- Lead Sponsor
- University of Parma
- Target Recruit Count
- 61
- Registration Number
- NCT01655758
- Locations
- 🇮🇹
University Eye Clinic, Parma, Italy
Clinical Evaluation of Efficacy of SLT to Topical Medication in Lowering IOP
- First Posted Date
- 2012-07-13
- Last Posted Date
- 2012-07-13
- Lead Sponsor
- Aurolab
- Target Recruit Count
- 600
- Registration Number
- NCT01639807
- Locations
- 🇮🇳
Aravind Eye Hospital, Madurai, Tamil Nadu, India
Switching From Preserved to Preserved-free Treatments for Glaucoma.
- First Posted Date
- 2011-09-14
- Last Posted Date
- 2014-05-16
- Lead Sponsor
- Paolo Fogagnolo
- Target Recruit Count
- 40
- Registration Number
- NCT01433900
- Locations
- 🇮🇹
San Paolo Hospital, Milano, Italy
Safety/Efficacy Study: OPA-6566 Ophthalmic Solution in Subjects With Primary Open-Angle Glaucoma or Ocular Hypertension
- Conditions
- Interventions
- First Posted Date
- 2011-08-05
- Last Posted Date
- 2014-03-11
- Lead Sponsor
- Kubota Vision Inc.
- Target Recruit Count
- 160
- Registration Number
- NCT01410188
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.